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A B S T R A C T
Background
Acute otitis media (AOM) is a very common early infancy and childhood disease. The marginal benefits of antibiotics on AOM, the
increasing problem of bacterial resistance to antibiotics, and the huge estimated direct and indirect annual costs associated with otitis
media (OM) have prompted a search for effective vaccines to prevent AOM.
Objectives
To assess the effect of pneumococcal conjugate vaccines (PCVs) in preventing AOM in children up to 12 years of age.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, issue 2), which contains the
Cochrane Acute Respiratory Infections Group’s Specialised Register; MEDLINE (January 1995 to November 2007); and EMBASE
(January 1995 to November 2007).
Selection criteria
Randomised controlled trials of PCVs to prevent AOM in children aged 12 years or younger, with a follow up of at least six months
after vaccination.
Data collection and analysis
Three review authors independently assessed trial quality and two review authors extracted data.
Main results
We included seven trials on 7- to 11-valent PCV (with different carrier proteins). There was large heterogeneity regarding study
population, type of conjugate vaccine, and outcome measures between trials, therefore, results were not pooled. The only currently
licensed 7-valent PCV Prevenar® with CRM197 as carrier protein (CRM197-PCV7) administered during infancy was in two studies
associated with a 6% (95% confidence interval (CI) -4% to 16%) and 7% (95% CI 4% to 9%) relative reduction in risk of AOM
episodes. Another 7-valent PCV with the outer membrane protein complex of Neisseria meningitidis (N. meningitidis) serogroup B as
carrier protein, administered in infancy, did not reduce overall AOM episodes, while an 11-valent PCV with Haemophilus influenzae
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(H. influenzae) protein D as carrier protein was associated with a relative reduction in risk of AOM episodes of 34% (95% CI 21%
to 44%). 9-valent PCV (with CRM197 carrier protein) administered in healthy toddlers was associated with a 17% (95% CI -2%
to 33%) relative reduction in risk of OM episodes. CRM197-PCV7 followed by 23-valent pneumococcal polysaccharide vaccination
administered after infancy in older children with a history of AOM showed no beneficial effect on further AOM episodes.
Authors’ conclusions
Based on current evidence of the effectiveness of PCVs for the prevention of AOM, the currently licensed 7-valent PCV administered
during infancy has marginal beneficial effects. Discrete reductions of 6% to 7% may mean substantial reductions from a public health
perspective. Administering PCV7 in older children with a history of AOM appears to have no benefit in preventing further episodes.
P L A I N L A N G U A G E S U M M A R Y
Pneumococcal conjugate vaccines for preventing otitis media
Acute otitis media (AOM) is the infection of the middle ear and is one of the most common diseases in childhood. Infection with
pneumococci (a type of bacterium) is a frequent cause of AOM. Pneumococcal conjugate vaccines (PCVs) aim to immunise young
children against pneumococcal infections. This review of seven trials with 46,885 participating children aimed to assess the effects of
PCV in preventing AOM. The only currently licensed 7-valent PCV given in infancy reduced the occurrence of AOM episodes by
6% to 7%. This means only a marginal decrease in AOM episodes for the individual, but this may have a substantial impact on the
healthcare burden of AOM. Children with a history of AOM do not seem to benefit from 7-valent PCV when immunised at an older
age (outside infancy).
B A C K G R O U N D
Description of the condition
Acute otitis media (AOM), defined as effusion in the middle ear
accompanied by one or more signs of acute inflammation in the
middle ear, such as otalgia, otorrhoea, fever, or irritability, is one
of the most common diseases in childhood, posing a large burden
on public health. It has a peak incidence in six- to 11-month-
olds (Teele 1989). By the age of one year, 62% of infants have
experienced at least one episode of AOM, and by the age of two
years up to 5% of all children have experienced recurrent episodes
of AOM, defined as at least four AOM episodes within one year
(Kvaerner 1997; Teele 1989). The three main bacterial pathogens
isolated from the middle ear fluid of children with AOM are
Streptococcus pneumoniae (S. pneumoniae) (25% to 39%), (non-
typeable) Haemophilus influenzae (H. influenzae) (12% to 23%),
andMoraxella catarrhalis (M. catarrhalis) (4% to 15%) (Bluestone
1992; Heikkinen 1999; Jacobs 1998; Luotonen 1981).
Description of the intervention
Themarginal benefits of antibiotics on AOM (Rovers 2006; Spiro
2008), the increasing problem of bacterial resistance against an-
tibiotics (Arason 1996; Dagan 2000; Del Castillo 1998; Goossens
2007), and the high estimated direct and indirect annual costs
associated with otitis media (OM) (Kaplan 1997; Niemela 1999)
have prompted a search for effective vaccines to prevent AOM.
How the intervention might work
With pneumococcus being the most common bacterial cause of
AOM and childhood pneumonia, and one of the most common
causes of invasive bacterial disease such as meningitis, research has
focused on the prevention of pneumococcal infections with pneu-
mococcal vaccines. Pneumococcal polysaccharide vaccines (PPVs)
have been available for decades, but have shown to be poorly
immunogenic in children below the age of two years which are
most prone to pneumococcal infections. The first pneumococcal
conjugate vaccines (PCVs) in which the pneumococcal capsular
serotypes are covalently conjugated to carrier proteins were devel-
oped in the 1990s and proved to be adequately immunogenic in
infants and toddlers (Dagan 1997; Eskola 1999; Shinefield 1999).
The focus in research shifted from the use of PPVs to PCVs in
children, and the role of PPVs in the prevention of AOM in chil-
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dren has merely been assessed following PCVs and not as a pri-
mary intervention anymore. Therefore, the focus of the current
review has shifted from the effect of PPVs to the effect of PCVs
on AOM. No further attention will be paid to the effect of PPVs,
which was described in prior versions of this review (Straetemans
2003).
O B J E C T I V E S
The aimof this reviewwas to assess the effect of PCVs inpreventing
AOM in children up to 12 years of age.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled clinical trials of PCVs with prevention of
AOM as an outcome in children aged 12 years or younger, and a
follow up after vaccinations of at least six months.
Types of participants
Children up to 12 years of age.
Types of interventions
Multivalent PCVs.
Types of outcome measures
The primary outcomes considered are the frequency of all AOM
episodes, pneumococcal AOM, and serotype-specific AOM, and
the proportion of children with frequent AOM (defined as at least
three episodes in the last six months or at least four episodes in
the last year).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (The Cochrane Library 2007, issue 2), which
contains the Cochrane Acute Respiratory Infections Group’s Spe-
cialised Register; MEDLINE (January 1995 to November 2007);
and EMBASE (January 1995 to November 2007).
We used the following search strategy for searching MEDLINE
and CENTRAL, and modified terms for searching EMBASE.
MEDLINE
#1 explode ‘bacterial-vaccine’ / all subheadings
#2 explode ‘bacterial AND vaccine’ / all subheadings
#3 explode ‘Pneumococcus-vaccine’ / all subheadings
#4 pneumococc* near immunity*
#5 pneumococc* near vaccin*
#6 #1 or #2 or #3 or #4 or #5
#7 explode ‘otitis media’ / all subheadings
#8 (otitis media in ti) or (otitis media in ab)
#9 #7 or #8
#10 #6 or #9
#11 explode ‘randomised-controlled-trial’ / all subheadings
#12 explode ‘controlled-study’ / all subheadings
#13 explode ‘randomisation’ / all subheadings
#14 explode ‘single-blind-procedure’ / all subheadings
#15 explode ‘double-blind-procedure’ / all subheadings
#16 explode ‘crossover-procedure’ / all subheadings
#17 explode ‘phase-3-clinical-trial’ / all subheadings
#18 (control* near trial*) in ti)
#19 (control* near trial*) in ab)
#20 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*)
in ti)
#21 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*)
in ab)
#22 random* near ((allocat* or assign*) in ti)
#23 random* near ((alsocat* or assign*) in ab)
#24 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #
19 or #20 or #21 or #22 or #23
#25 #10 and #24
Searching other resources
We also identified studies by checking the bibliographies of all
studies and review articles retrieved. We imposed no language
restrictions on the searches.
Data collection and analysis
Study quality and data extraction
Three review authors (AJ, LS and EH) assessed quality of the in-
cluded studies using a three-item quality scale with a score range
from zero to five (Jadad 1996). According to the Jadad criteria,
one point was allocated for randomisation, double blinding and
description of withdrawals and dropouts; an extra point was added
for methods of randomisation and blinding that are well described
and adequate. Studies that used a clearly inadequate method of
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randomisation or blinding lost the point allocated. We resolved
disagreement by discussion. The Jadad score may vary from zero
to five, equalising the minimal and maximal quality score accom-
plished. The same authors performed data extraction indepen-
dently, and resolved differences by consensus.
Data analysis
Meta-analysis by pooling the results of the different studies is only
useful and justified when studies show satisfactory clinical homo-
geneity in terms of study population, setting, intervention andout-
comemeasures. We assessed clinical heterogeneity between studies
by reviewing the differences across trials. There was considerable
clinical heterogeneity in the trials in terms of the study popula-
tions, outcome measures, and the type of PCV regarding carrier
protein and valency (see ’Description of studies’ below). There-
fore, we decided a meta-analysis was not appropriate.
We briefly describe the methods we would have used if we pooled
the results. The generalised Cox proportional hazard method
proposed by Anderson and Gill (Andersen 1982) is regarded
as the most appropriate to assess the effect of PCVs on AOM
(Jahn-Eimermacher 2007). Under the assumptions that the hazard
rate is proportional between both groups over time, and that the
risk of AOM is not affected by previous episodes (although this
assumption is most likely not true), this model takes all available
information into account; that is, all episodes (also the recurrent
ones), differences in individual patient follow-up time, and time
until a case of AOM (Jahn-Eimermacher 2007). However, infor-
mation on individual follow-up time until the first, second, third,
etc case of AOM is hard to obtain for each study to be included
in the meta-analysis. Poisson regression is based on the assump-
tions of a constant risk of AOM over time and that this risk is
not affected by previous episodes of AOM. This method only re-
quires the total follow-up time and total number of episodes and
appears therefore a more feasible method to meta-analyse. Fur-
thermore, Poisson regression seems not to be affected by the de-
viation from a constant risk over time, having very similar results
for the effect of PCVs on AOM to the Anderson-Gill approach
(Jahn-Eimermacher 2007). For Poisson regression, the treatment
effect is measured as a rate ratio defined as follows: (total AOM
episodes in pneumococcal vaccination group divided by the num-
ber of children in the pneumococcal vaccination group multiplied
by the follow-up time in months) divided by (total AOM episodes
in control group divided by the number of children in the control
group multiplied by the follow-up time in months) (McCullagh
1989).
R E S U L T S
Description of studies
The MEDLINE search yielded eight potentially relevant ran-
domised trials after screening of the title and abstract (Black 2000;
Dagan 2001; Eskola 2001; Fireman 2003; Kilpi 2003; Prymula
2006; Van Kempen 2006; Veenhoven 2003). We found no ad-
ditional potentially relevant trials in either CENTRAL or the
Cochrane Acute Respiratory Infections Group Specialised Regis-
ter. The EMBASE search also did not yield any additional poten-
tially relevant studies.
The eight included papers in this review concerned seven studies in
total. Two of these studies (Black 2000/Fireman 2003 and Dagan
2001) had all types of OM (including but not exclusively AOM) as
an outcome. Since the effect of PCVs on AOMmay be influenced
by the age at which the PCVwas administered, wewill describe the
studies accordingly, that is, those with vaccination in infancy and
those with vaccination later in childhood. In all studies the control
group received a control vaccine. See also the ’Characteristics of
included studies’ table.
PCV administered in infancy
Three trials including healthy infants studied the effect of PCV
administered in infancy onOM. In theNorthernCaliforniaKaiser
Permanente (NCKP) trial (Black 2000/Fireman 2003) and the
Finnish Otitis Media (FinOM) trial (Eskola 2001) the treatment
group was administered the 7-valent PCV, containing the polysac-
charides of seven serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F cou-
pled to the carrier protein CRM197 (a non-toxic mutant of diph-
theria toxin) (CRM197-PCV7), at the age of two, four and six
months, and 12 to 15 months. In the NCKP trial, infants were
enrolled over a period of almost three years and had a follow-up
time varying from about eight months to 3.5 years. The trial was
originally designed to investigate the effect of CRM197-PCV7
on invasive pneumococcal disease, and OM was a secondary out-
come. Clinical diagnoses of OM were obtained from a comput-
erised database collecting department-specific diagnosis checklists
routinely marked by emergency physicians and paediatricians in
the NCKP population. All clinical diagnoses of ’otitis media’, ’oti-
tis media, acute’, ’middle ear effusion’, ’otitis media, serous’, or
’otitis media with effusion’ were included. The FinOM trial pri-
marily aimed to assess the effect on AOM. Infants were followed
until the age of 24 months, and parents were encouraged to bring
their child to the study clinic (established specifically for the pur-
pose) for evaluation of symptoms suggesting respiratory infection
or AOM. The diagnosis of AOM was standardised.
Kilpi 2003 describes another part of the FinOM trial in which the
index group was administered another 7-valent PCV, containing
capsular polysaccharides of the same seven serotypes as CRM197-
PCV7 conjugated to the outermembrane protein complex ofNeis-
seria meningitidis (N. meningitidis) serogroup B (OMPC-PCV7).
Additionally, 22% of the children assigned to OMPC-PCV7 re-
ceived PPV23 at the age of 12 months instead of a fourth OMPC-
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PCV7 dose. The follow up and outcome measure was similar to
Eskola 2001. Finally, in Prymula 2006 (POET trial) an 11-valent
PCVwas administered at the ages of two, four, fivemonths, and 12
to 15months, containing the capsular polysaccharides of serotypes
1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, conjugated to protein
D, which is a surface lipoprotein of H. influenzae. Protein D is
highly conserved in both encapsulated and non-encapsulated H.
influenzae strains and therefore has the potential to provide pro-
tection against any H. influenzae strain that causes OM (Forsgren
2008; Prymula 2006). Follow up continued until the age of 24 to
27 months. The primary aim of the trial was to assess the effect
on AOM, and parents were advised to consult their paediatrician
if their child was sick, had ear pain, or had spontaneous ear dis-
charge. The diagnosis of AOM was standardised.
PCV administered at a later age
Three trials assessed the effects of PCV administered at a later age
on AOM. Dagan 2001 assessed the effect of a 9-valent PCV (con-
taining the capsular polysaccharides of serotypes 1 and 5 besides
those included in CRM197-PCV7, conjugated to CRM197) on
AOM in healthy daycare attendees aged 12 to 35 months. The
vaccine was administered twice in 12- to 17-month-olds and once
in 18- to 35-month-olds. The study was undertaken to examine
the effect on respiratory infections. In 18 encounters during the
two-year follow-up period that started one month after complete
immunisation, parents were questioned about illness episodes, in-
cluding OM episodes. The OM diagnosis was not physician con-
firmed and not standardised. Van Kempen 2006 and Veenhoven
2003 assessed the effect of pneumococcal vaccination on AOM in
children aged one to seven years with a history of at least two AOM
episodes in the year prior to study entry. CRM197-PCV7 was
administered twice in one- to two-year-olds and once in two- to
seven-year-olds followed by PPV23 (containing capsular polysac-
charides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A,
11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) six
to seven months later. Children with underlying illnesses includ-
ing immunocompromising conditions were excluded. Both stud-
ies had a similar design, were conducted in parallel but were anal-
ysed separately due to differences in study population (children
included in Van Kempen 2006 had a more severe history of AOM
and more often tympanostomy tube placement prior to study en-
try). Follow-up lasted about 24 months. Parents were instructed to
visit the study clinics or their family physician, otolaryngologists,
or paediatrician for assessment in case of symptoms suggesting
AOM. Physicians registered signs and symptoms of every AOM
episode on standard registration forms. The diagnosis of AOM
was standardised.
Risk of bias in included studies
Table 1 shows the results of the quality assessment by the Jadad
method (Jadad 1996). Dagan 2001, Van Kempen 2006 and Veen-
hoven 2003 had a maximum quality score of five. Kilpi 2003
scored four points because this article failed to report withdrawals
and dropouts, while adequately reporting the randomisation and
double-blinding methods. Prymula 2006 scored four points and
missed one point due to no reporting of double-blinding methods.
Black 2000 and Fireman 2003 had a quality score of two. Both ar-
ticles failed to report withdrawals and dropouts, and no additional
points could be given for adequate reporting of the method to
generate the sequence of randomisation and themethod of double
blinding. Eskola 2001 had a score of two for similar reasons. Al-
though this study reported the number of withdrawals and drop-
outs, no reasons were given for them.
This review will present the results of the trials as reported in
the published papers since meta-analysis was decided to be inap-
propriate due to heterogeneity in study population, intervention
and outcome measure. Therefore the statistical methods by which
the data were analysed in each study are shortly assessed. Black
2000, Eskola 2001, Fireman 2003, Kilpi 2003, Prymula 2006,
Van Kempen 2006 and Veenhoven 2003 all used the generalised
Cox proportional hazard method proposed by Anderson and Gill
1982 (Andersen 1982), currently regardedmost optimal to analyse
this kind of data (see ’Data collection and analysis’ section above).
Dagan 2001 compared rates of AOM, but rather than comparing
them by Poisson regression (which would presumably yield results
similar to those obtained with the Anderson and Gill approach),
the chi-square test was used, which is suboptimal for comparing
rates.
Effects of interventions
In total, we included seven trials with 46,885 participating chil-
dren, ranging from 74 to 37,868 participants per study. Four stud-
ies included infants who received primary vaccinations before six
months of age (46,164 participants in total) (Black 2000/Fireman
2003; Eskola 2001; Kilpi 2003; Prymula 2006); one study in-
cluded daycare attendees aged 12 to 35 months (264 participants)
(Dagan 2001), and two included one- to seven-year-olds with a
history of AOM (457 participants in total) (Van Kempen 2006;
Veenhoven 2003).
In four studies the licensed CRM197-PCV7 was used as interven-
tion (Black 2000/Fireman 2003; Eskola 2001; Veenhoven 2003;
Van Kempen 2006), and in two of these studies boosting with
23-valent PPV was given (Van Kempen 2006; Veenhoven 2003).
The other three studies each had different interventions, i.e. a 9-
valent PCV with CRM197 as protein carrier (Dagan 2001), a 7-
valent PCV with the outer membrane complex of N. meningitidis
serogroup B as protein carrier (Kilpi 2003), and an 11-valent PCV
with protein D as protein carrier (Prymula 2006).
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All studies had a control group that was given a control vaccine
(meningococcus type C conjugate vaccine, hepatitis A vaccine or
hepatitis B vaccine). Five studies applied a standardised diagnosis
of AOM (Eskola 2001; Kilpi 2003; Prymula 2006; Van Kempen
2006; Veenhoven 2003), whereas in one study, AOM episodes
were extracted from a computerised data source containing all
visits registered by physicians (Black 2000/Fireman 2003) and
another study assessed parent-reported AOM episodes (Dagan
2001). Five studies additionally assessed the effect of PCVs on
pneumococcal AOM (Black 2000/Fireman 2003; Eskola 2001;
Kilpi 2003; Prymula 2006; Veenhoven 2003). Three studies cul-
tured middle ear fluid from all AOM episodes (Eskola 2001; Kilpi
2003; Prymula 2006), whereas one study only cultured it from the
first AOM episode (Veenhoven 2003), and another study assessed
the effect on reported cultures that were taken in cases of sponta-
neously draining ears (Black 2000/Fireman 2003). Three studies
reported on the effects of PCVs on recurrent AOM (Black 2000/
Fireman 2003; Eskola 2001; Prymula 2006).
It should be noted that we have presented the results of the tri-
als included in this review as reported in the published papers
and that the presentation of results varied between trials. Where
possible we have reported the incidences of the various outcomes
in the study arms together with the efficacy estimates with 95%
CIs. However, due to limitations of the data, we have reported
alternative statistical measures in some instances. Most studies re-
ported efficacy estimates on the basis of per-protocol-analysis with
or without noting that estimates on the basis of intention-to-treat-
analysis were similar.
See also Table 2, Table 3, and Table 4 for the efficacy estimates of
PCVs on all AOM episodes, pneumococcal AOM, and recurrent
AOM respectively.
Effect of PCV administered in infancy
The NCKP and FinOM trials in which CRM197-PCV7 was ad-
ministered during infancy showed that CRM197-PCV7 reduced
overall AOMepisodes by 6% to 7% (Eskola 2001; Fireman 2003),
whereasOMPC-PCV7appeared tohave no effect onoverall AOM
episodes (Kilpi 2003). The administration of protein D PCV11
during infancy was associated with a 34% reduction in AOM
episodes (Prymula 2006).
Efficacy of PCVs administered in infancy against pneumococcal
AOM varied from 25% for OMPC-PCV7 (Kilpi 2003), 34% for
CRM197-PCV7 (Eskola 2001), to 52% for protein D PCV11
(Prymula 2006). The reduction of vaccine-type pneumococcal
AOM was fairly similar with 56% to 67% (Black 2000; Eskola
2001; Kilpi 2003; Prymula 2006). Administration of CRM197-
PCV7 and protein D PCV11 also seemed to reduce AOM caused
by the so-called cross-reactive serotypes which are non-vaccine
serotypes with a serogroup that is included in the vaccine (Eskola
2001; Prymula 2006), while OMPC-PCV7 failed to show cross-
protection (Kilpi 2003). Although not statistically significant,
the administration of CRM197-PCV7 and OMPC-PCV7 was
associated with an increase in non-vaccine-type AOM (replace-
ment) (Eskola 2001; Kilpi 2003) and H. influenzae AOM while
the protein D PCV11 did not show pneumococcal replacement
and showed vaccine efficacy of 35% against H. influenzae AOM
(Prymula 2006).
CRM197-PCV7 seemed to reduce recurrent AOM by 9% (Black
2000; Eskola 2001), whereas the administration of protein D
PCV11 was associated with a statistically non-significant decrease
of 56% in recurrent AOM (Prymula 2006).
Effect of PCV administered at a later age
9-valent PCV administered in healthy 12- to 35-month-olds ap-
peared to reduce overall OM episodes by 17% (Dagan 2001),
while CRM197-PCV7 followed by PPV23 in one- to seven-year-
olds with a history of AOM did not reduce the occurrence of fur-
ther AOM episodes (Van Kempen 2006; Veenhoven 2003). With
respect to pneumococcal AOM, only one study reported the effect
of CRM197-PCV7 followed by PPV23 on pneumococcal AOM
(Veenhoven 2003): pneumococcal AOM was reduced by 33%,
vaccine-type AOM by 56%, and non-vaccine type AOM by 17%,
although none of the estimates was statistically significant (small
numbers). None of the three trials in older children reported the
effect of the PCV on recurrent AOM.
D I S C U S S I O N
The trials on the effect of PCV on AOM in children show large
heterogeneity regarding study population (age of administration
of PCV), intervention (vaccine valency (7-/9-/11-valent vaccines),
carrier protein (CRM197, OMPC or protein D), presence or ab-
sence of additional booster immunisation with PCV or PPV23,
and outcomes (active surveillance for standardised physician-di-
agnosed AOM, passive collection of diagnoses of AOM or parent-
reported AOM). Furthermore, in the infant studies on AOM fo-
cusing on bacteriology (Eskola 2001; Kilpi 2003; Prymula 2006)
the control groups varied markedly in the proportions of S. pneu-
moniae,H. influenzae andM. catarrhalis in middle ear fluid, possi-
bly related to time and geographic region as well as case definition
which will affect the result of overall AOM episodes prevented by
pneumococcal vaccines. Additionally, two studies (Van Kempen
2006; Veenhoven 2003) included older otitis-prone children with
tympanostomy tubes, so the intervention was aimed at secondary
or even tertiary, not primary prevention.
The currently licensed CRM197-PCV7, a 7-valent pneumococ-
cal conjugate vaccine with CRM197 as carrier protein, admin-
istered in infancy was associated with a 6% to 7% reduction in
AOM episodes (Eskola 2001; Fireman 2003). The 7-valent PCV
with OMPC as carrier protein appeared to have less effect on
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AOM episodes overall than CRM197-PCV7 (Kilpi 2003). This
despite the fact that both 7-valent vaccines appeared to have a
similar effect on vaccine-serotype pneumococcal AOM of 56%
and 57% (Eskola 2001; Kilpi 2003). However, CRM197-PCV7
also showed cross-protection to vaccine-related serotypes, in par-
ticular to the very common vaccine-related 6A serotype (Eskola
2001), while OMPC-PCV7 showed no efficacy at all against vac-
cine-related serotypes like 6A (Kilpi 2003). For both 7-valent vac-
cines, there was a tendency of replacement disease by non-vaccine
pneumococci as well as by other otopathogens like H. influen-
zae. Furthermore, in the OMPC-PCV7 arm of the FinOM trial,
the proportion of AOM caused by M. catarrhalis also increased
(Kilpi 2003). This means that PCVs are effective against vaccine-
serotype pneumococci, but in AOM there is high potential for
replacement by other pathogens that are common colonisers of
the nasopharynx. CRM197-PCV7 is known to affect nasopha-
ryngeal carriage of pneumococci, with a shift from vaccine-type
pneumococci to non-vaccine-type pneumococci and other bacte-
rial pathogens that may have pathogenic potential (Block 2006;
Eskola 2001; Obaro 1996; Veenhoven 2003; Veenhoven 2004).
The middle ear is directly connected to the nasopharynx and by
lowering the carriage of vaccine-type pneumococci, a niche is cre-
ated for other bacteria with a pathogenic potential (Block 2006;
Veenhoven 2003; Veenhoven 2004).
Although the vaccine-related serotypes, mostly notably 6A and
19A, were reduced after CRM197-PCV7 in the FinOM trial (
Eskola 2001), the name ’cross-protection’ by the vaccine should
probably be abandoned. In post-marketing studies after licensure
of CRM7-PCV7 in the US in 2000, an increase in serotype 19A
in invasive pneumococcal disease as well as an increase in serotype
6A and 19A involved in AOM was observed (Block 2004; Hicks
2007; McEllistrem 2005; Pichichero 2007). Both upcoming ear
pathogens (pneumococcal serotypes 6A and 19A) are included in a
13-valent CRM197-conjugate vaccine that is under development.
The POET trial with an 11-valent PCV with protein D as carrier
protein administered to infants, reported the largest reduction in
overall AOM episodes of 34% (Prymula 2006). Compared to the
6% to 7% reduction in studies with CRM197-PCV, this effect is
rather large and may not be solely explained by the four additional
serotypes covered by the 11-valent PCV compared to CRM197-
PCV7. Part of the effect may be related to the protein D to which
the polysaccharides are conjugated in the vaccine. Protein D has
the potential to provide protection against anyH. influenzae strain
that causes OM (Forsgren 2008; Prymula 2006). Indeed, the 11-
valent PCV with protein D as carrier protein was demonstrated
to reduce non-typeable H. influenzae by 35% (95% CI 2 to 57)
(Prymula 2006). Furthermore, an effect against vaccine-related
serotypes was observed in the POET trial and remarkably, no re-
placement by non-vaccine serotypes was demonstrated. It should
be noted that in the POET trial children diagnosed with AOM by
the paediatrician were subsequently referred to the otorhinolaryn-
gologist for confirmation and collection of middle ear fluid, while
in the FinOM trial middle ear fluid was collected from every child
with a diagnosis of AOM during the same visit. This may have
contributed to the large difference in AOM incidence between
these studies with incidence rates reported by Prymula 2006 being
about ten times lower than the incidence reported by Eskola 2001.
It might be that in the POET trial the more severe episodes of
AOM were identified and consequently the effect may only apply
to these more severe episodes. The case definition potentially also
introduced a different selection of pathogens.
Only one trial reported on the effects of PCV on AOM in older
healthy children, daycare attendees (Dagan 2001). After admin-
istration of a 9-valent PCV with CRM197 as carrier protein, a
17% reduction in AOM was observed. However, in this study
the outcome measure (parent-reported AOM) and the statistics
were suboptimal. The other studies in older children aged one
to seven years concern children with a history of AOM (Van
Kempen 2006; Veenhoven 2003). In these studies, the admin-
istration of CRM197-PCV7 was followed by PPV23, and both
showed no beneficial effect on further AOM episodes overall after
the PPV booster. In contrast, in the infant studies with CRM197-
PCV7 but without the PPV23 booster, a protective effect on the
number of children developing recurrent episodes of AOM up
to 16% was demonstrated. This was also reflected in a 20% re-
duction of tympanostomy tube placement (Black 2000; Fireman
2003). The point estimate of vaccine efficacy in the children vac-
cinated at an older age but after previous AOM episodes indicated
a similar reduction of AOM caused by vaccine-serotypes to the
FinOM study with CRM197-PCV7 (Eskola 2001; Kilpi 2003;
Veenhoven 2003). Furthermore, a significant and adequate na-
sopharyngeal carriage reduction of vaccine-type pneumococci was
observed (Veenhoven 2004). The reduced efficacy of CRM197-
PCV7 in children alreadywith a history of AOMmay be explained
by an increased susceptibility to subsequent infections, not only
with non-vaccine type pneumococci but also other nasopharyn-
geal colonisers, due to ‘damages’ already suffered by the middle
ear mucosa caused by prior AOM (Veenhoven 2003). Thus, it ap-
pears that the age at which PCV is administered and/or a history
of AOM episodes modifies the effect of PCV on AOM, despite
the fact that age alone could not be identified as a statistically sig-
nificant effect modifier (Fireman 2003; Veenhoven 2003).
The real-world experience gained with widespread CRM197-
PCV7 vaccination in infants after 2000 in the United States sug-
gests that the impact on AOMmay bemuch greater than that seen
in the clinical studies. Post-licensure studies comparing rates of
ambulatory visits and antibiotic prescriptions related to AOM in
the immediate years before and following widespread implemen-
tation of routineCRM197-PCV7 vaccination in children younger
than two years of age, found a reduction of 42.7% and 41.9%
respectively (Zhou 2008), and another study found a decline in
frequent OM of 17% and 28% in birth cohorts from Tennessee
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and upstate New York (Poehling 2007). These much higher bene-
fits might be due to indirect herd effects and may have important
implications for the cost-effectiveness analyses for conjugate vac-
cines. However, in a recent study in the Boston area, the decline
of uncomplicated AOM, as well as (OM) treatment failure and
AOM relapse showed that the decline was at least as much in the
period 1996 to 2000 as from 2000 to 2004 and therefore the role
of PCV implementation for OM may be modest (Sox 2008).
Whether the decline in OM will continue or wane with time is
relevant and deserves ongoing monitoring. A waning effect in OM
incidence after implementation of conjugate vaccinations may be
explained by replacement by other otopathogens like H. influen-
zae or an increase in the proportion of OM caused by non-vac-
cine serotypes including serotypes 3, 6A and 19A (Block 2004;
McEllistrem 2005; Pichichero 2007). As previously mentioned,
two infant studies found an increase in non-vaccine-type pneumo-
coccal AOM after administration of 7-valent PCV, albeit not sta-
tistically significant, as well as an increase of H. influenzae (Eskola
2001; Kilpi 2003). An increase inH. influenzae was also observed
in the postmarketing studies on AOM in the United States (Block
2004; Casey 2004). In addition, the study in older children with
previous AOMepisodes demonstrated an increase of AOMcaused
by Staphylococcus aureus (S. aureus) (Veenhoven 2003).Continuing
research after the effects of PCV on nasopharyngeal carriage and
on AOM before and after the introduction of CRM197-PCV7
in national infant immunisation protocols is therefore of utmost
importance.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When administered in infancy, PCVs appear to have some pro-
tective effect against AOM, depending on the type of PCV used.
At present, CRM197-PCV7, a 7-valent PCV with CRM197 as
carrier protein, is the only PCV licensed for use in young children.
The prevention of invasive pneumococcal disease has been the pri-
mary reason for many Western countries to introduce CRM197-
PCV7 into their national infant immunisation protocol. The ben-
eficial effect on overall AOM episodes with the currently licensed
7-valent vaccine appears marginal with a 6% to 7% reduction,
and therefore promoting CRM197-PCV7 solely to reduce AOM
for the individual does not seem justified. However, from a public
health perspective, because AOM is so common, even such small
reductions may substantially reduce the health care burden caused
by AOM.
For countries that have not yet implemented CRM197-PCV7
into the immunisation protocol and for countries that did not
implement a catch-up vaccination programme for older children
up tofive years of age, the question iswhether it would be beneficial
to administer the vaccine to older children with a history of AOM.
The two trials in older children with a history of AOM suggested
no beneficial effect of CRM197-PCV7 on all further episodes of
AOM (Van Kempen 2006; Veenhoven 2003), and consequently,
there is no reason at present to administer older children with a
history of previous AOM episodes the vaccine in order to protect
them against further AOM episodes. In fact, early vaccination
before the first AOM episode may be required for prevention of
middle ear mucosal damage.
Implications for research
The Jadad quality analysis is very sensitive to written information
from published manuscripts. Most studies included in this review
lost points because the method of randomisation or blinding was
not described. Also, often points were lost because the reasons for
withdrawals and dropouts were not described. Future publications
of trials should clearly report these items.
In view of the ongoing development of new PCVs and studies on
these, we emphasise the need for uniform outcome measures (case
definitions of AOM) and presentation of results to allow for meta-
analysis by pooling the results in future. Reporting of the total
number of AOM episodes in the different study arms, together
with the total follow-up time in person-months is required. These
figures should also be available on the basis of intention-to-treat
analysis and not only on the basis of per-protocol-analysis.
Eleven-valent PCV with protein D as carrier protein appears
promising in the prevention of AOM, and currently trials are ini-
tiated to determine the effect of this vaccine on pneumococcal
disease. Also the newly developed 13-valent PCV (with CRM197
as carrier protein and the additional serotypes 1, 3, 5, 6A, 7F, and
19A besides those included in CRM197-PCV7) may mean an
improvement in the protection against pneumococcal infections,
including AOM.
In view of the effects of PCVs on nasopharyngeal carriage of
pathogens, awareness of the possibility of infections caused by re-
placing pathogens is warranted. Besides reduction of nasopharyn-
geal vaccine-type serotypes which is presumed to induce herd ef-
fects, replacing pneumococcal serotypes may not only lead to re-
placement disease in vaccinees but also in the population. Con-
tinuing surveillance of pneumococcal disease in different settings
and geographic locations is therefore of utmost importance.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Black 2000
Methods Randomised controlled, double-blind trial
Participants US multicentre trial of 37,868 healthy infants aged 2 months
Interventions 7-valent pneumococcal conjugate vaccine (containing the polysaccharides of serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F conjugated to the carrier protein CRM197) at 2, 4, 6, and 12 to 15 months of age versus
meningococcus type C conjugate vaccine at similar ages
Outcomes Recurrent episodes/visits of otitis media - episodes extracted from a computerised data source containing
all visits registered by physicians
These were secondary outcomes; the trial was originally designed to assess the effect of the vaccine on
invasive pneumococcal disease
Notes Fireman 2003 is an extension of this study
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Dagan 2001
Methods Randomised controlled, double-blind trial
Participants Israeli trial of 264 healthy 12- to 35-month-olds attending eight daycare centres
Interventions 9-valent pneumococcal conjugate vaccine (containing saccharides of nine serotypes 1, 4, 5, 6B, 9V, 14,
18C, 19F and 23F conjugated to CRM197) twice in 12- to 17-month-olds and once in 18-to 35-month-
olds versus meningococcus type C vaccination at similar ages
Outcomes Otitis media episodes, parent-reported
This was a secondary outcome; primary outcome of the trial was nasopharyngeal carriage of S. pneumoniae
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
12Pneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eskola 2001
Methods Randomised controlled, double-blind trial
Participants Finland, multicentre trial of 1662 infants aged 2 months
Interventions 7-valent pneumococcal conjugate vaccine (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F conjugated to the carrier protein CRM197) at 2, 4, 6, and 12 to 15 months of age versus
hepatitis B vaccine at similar ages
Outcomes Recurrent AOM episodes + AOM due to S. pneumoniae/non-vaccine type pneumococcal AOM
AOM diagnosed by otoscopy (presence of abnormal tympanic membrane in terms of colour, position,
or mobility, suggesting middle-ear effusion, plus at least one of the following symptoms or signs of acute
infection (fever, earache, irritability, diarrhoea, vomiting, acute otorrhoea not caused by otitis externa, and
other symptoms of respiratory infection)
Notes This trial was part of a study including Kilpi 2003. Both Eskola 2001 and Kilpi 2003 used the same
control group but a different index group, each with a different type of 7-valent pneumococcal conjugate
vaccine
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Fireman 2003
Methods see Black 2000
Participants see Black 2000
Interventions see Black 2000
Outcomes see Black 2000
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Kilpi 2003
Methods Randomised controlled, double-blind trial
Participants Finland, multicentre trial of 1666 infants aged 2 months
Interventions 7-valent pneumococcal conjugate vaccine (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F conjugated to the outer membrane protein complex of N. meningitidis serogroup B) at
2, 4, 6, and 12 months of age versus hepatitis B vaccine at similar ages. 22% of the children assigned
to receive the 7-valent pneumococcal conjugate vaccine received 23-valent pneumococcal polysaccharide
vaccination instead (containing saccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A,
12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) at the age of 12 months
Outcomes See Eskola 2001
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Prymula 2006
Methods Randomised controlled, double-blind trial
Participants Czech Republic/Slovakian multicentre trial of 4,968 infants aged between 6 weeks and 5 months
Interventions 11-valent pneumococcal conjugate vaccine (containing polysaccharides of the serotypes 1, 3, 4, 5, 6B, 7F,
9V, 14, 18C, 19F, and 23F conjugated to protein D (surface lipoprotein of H. influenzae) at ages of ~ 2,
4, 5, and 12 to 15 months versus hepatitis A vaccines at similar ages
Outcomes Recurrent AOM episodes + AOM due to S. pneumoniae, (non) vaccine type pneumococcal AOM
AOM diagnosed by either the visual appearance of the tympanic membrane (i.e. redness, bulging, loss
of light reflex) or the presence of middle-ear effusion (as shown by simple or pneumatic otoscopy or by
microscopy). The presence of at least two of the following signs or symptoms was required: earache, ear
discharge, hearing loss, fever, lethargy, irritability, anorexia, vomiting or diarrhoea (these symptoms had
to have started within the 14 days preceding the clinical diagnosis)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Van Kempen 2006
Methods Randomised controlled, double-blind trial
Participants Belgian trial of 74 one- to seven-year-olds with at least two acute otitis media episodes in the year before
study entry
Interventions 7-valent pneumococcal conjugate vaccine (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F conjugated to the carrier protein CRM197) twice in 12- to 24-month-olds and once in 2-
to -year-olds followed by 23-valent pneumococcal polysaccharide vaccination (containing polysaccharides
of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F,
23F, and 33F) respectively 6 and 7 months later versus hepatitis A vaccination in a similar time schedule
Outcomes AOM episodes diagnosed as the presence of an abnormal tympanic membrane on otoscopy (red, dull,
or bulging), or otorrhoea and at least one of these signs or symptoms of acute infection: earache, acute
otorrhoea, irritability, or fever (greater than 38.5°C rectally)
Notes Performed in parallel with the study of Veenhoven 2003 but analysed separately due to differences in
study population
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Veenhoven 2003
Methods Randomised controlled, double-blind trial
Participants Dutch trial of 383 1- to 7-year-olds with at least two acute otitis media (AOM) episodes in the year before
study entry
Interventions 7-valent pneumococcal conjugate vaccine (containing polysaccharides of serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F conjugated to the carrier protein CRM197) twice in 12- to 24-month-olds and once in 2-
to 7-year-olds followed by 23-valent pneumococcal polysaccharide vaccination (containing saccharides of
the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F,
and 33F) respectively 6 and 7 months later versus respectively hepatitis B or hepatitis A vaccination in a
similar time schedule
Outcomes AOM episodes + AOM due to Streptococcus pneumoniae/ (non) vaccine type pneumococcal AOM
AOM diagnosed as the presence of an abnormal tympanic membrane on otoscopy (red, dull, or bulging)
, or otorrhoea and at least one of these signs or symptoms of acute infection: acute earache, new-onset
otorrhoea, irritability, or fever greater than 38.5°C rectally or 38.0°C axillary
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
15Pneumococcal conjugate vaccines for preventing otitis media (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Veenhoven 2003 (Continued)
Allocation concealment? Low risk A - Adequate
AOM = acute otitis media
PCV = pneumococcal conjugate vaccine
A D D I T I O N A L T A B L E S
Table 1. Methodological quality of included studies.
Study Randomised R appropriate? Double blinded DB appropriate? Withdrawals/
dropouts
Total score
Black (2000) 1 0 1 0 0 2
Eskola (2001) 1 0 1 0 0 2
Dagan (2001) 1 +1 1 +1 1 5
Fireman (2003) 1 0 1 0 0 2
Kilpi (2003) 1 +1 1 +1 0 4
Veenhoven
(2003)
1 +1 1 +1 1 5
Van Kempen
(2006)
1 +1 1 +1 1 5
Prymula (2006) 1 +1 1 0 1 4
R = Randomisation
DB = Double blinding
Table 2. The effect of pneumococcal conjugate vaccination on acute otitis media episodes
Pneumococcal conjugate vaccination administered in infancy
Episodes/person year Relative reduction in risk (95% confidence interval)
Index Control
Intention-to-treat analysis
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Table 2. The effect of pneumococcal conjugate vaccination on acute otitis media episodes (Continued)
Firemean 2003 not reported not reported 6% (4 to 8)
Eskola 2001 not reported not reported not reported
Kilpi 2003 not reported not reported not reported
Prymula 2006 not reported not reported not reported
Per-protocol analysis
Firemean 2003 not reported not reported 7% (4 to 9)
Eskola 2001 1.16 1.24 6% (-4 to 16)
Kilpi 2003 not reported not reported -1% (-12 to 10)
Prymula 2006 0.08 0.13 34% (21 to 44)
Pneumococcal conjugate vaccination administered at a later age
Episodes/person year Relative reduction in risk (95% confidence interval)
Index Control
Intention-to-treat analysis
Dagan 2001 0.66 0.79 17% (-2 to 33)
Veenhoven 2003 not reported not reported -25% (-57 to 1)
Van Kempen 2006 not reported not reported not reported
Per-protocol analysis
Dagan 2001 Not reported Not reported Not reported
Veenhoven 2003 1.1 0.83 -29% (-62 to -2)
Van Kempen 2006 0.78 0.67 -16% (-96 to 31)
Note: negative values represent an increase in the risk for AOM
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Table 3. The effect of pneumococcal conjugate vaccination on pneumococcal acute otitis media
Pneumococcal conjugate vaccination administered in infancy
Relative reduction in risk (95% confidence interval); P-value
Pneumococcal AOM Vaccine- type AOM Non-vaccine-type AOM
Intention-to-treat analysis
Black 2000 not reported 65%, P = 0.035 not reported
Eskola 2001 not reported 54% (41 to 64) not reported
Kilpi 2003 not reported not reported not reported
Prymula 2006 not reported not reported not reported
Per-protocol analysis
Black 2000 not reported 67%, P = 0.077 not reported
Eskola 2001 34% (21 to 45) 57% (44 to 67) cross-reactives: 51% (27 to 67)
others: -33% (-80 to 1)
Kilpi 2003 25% (11 to 37) 56% (44 to 66) cross-reactives: -5% (-47 to 25)
others: -27% (-70 to 6)
Prymula 2006 52% (37 to 63) 58% (41 to 69) cross-reactives: 66% (22 to 85)
others: 9% (-64 to 49)
Pneumococcal conjugate vaccination administered at a later age
Relative reduction in risk (95% confidence interval); P-value
Pneumococcal AOM Vaccine- type AOM non-vaccine-type AOM
Intention-to-treat analysis
Dagan 2001 not reported not reported not reported
Veenhoven 2003 not reported not reported not reported
Van Kempen 2006 not reported not reported not reported
Per-protocol analysis
Dagan 2001 not reported not reported not reported
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Table 3. The effect of pneumococcal conjugate vaccination on pneumococcal acute otitis media (Continued)
Veenhoven 2003 34%, P = 0.22 52%, P = 0.21 21%, P = 0.44
Van Kempen 2006 not reported not reported not reported
Note: negative values represent an increase in the risk for AOM
Table 4. The effect of pneumococcal conjugate vaccination on recurrent acute otitis media
Pneumococcal conjugate vaccination administered in infancy
Relative reduction in risk (95% confidence interval)
Intention-to-treat analysis
Black 2000 9% (4 to 14)
Eskola 2001 9% (-12 to 27)
Kilpi 2003 not reported
Prymula 2006 not reported
Per-protocol analysis
Black 2000 9% (3 to 15)
Eskola 2001 16% (-6 to 35)
Kilpi 2003 not reported
Prymula 2006 56% (-2 to 81)
Pneumococcal conjugate vaccination administered at a later age
Relative reduction in risk (95% confidence interval)
Intention-to-treat analysis
Dagan 2001 not reported
Veenhoven 2003 not reported
Van Kempen 2006 not reported
Per-protocol analysis
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Table 4. The effect of pneumococcal conjugate vaccination on recurrent acute otitis media (Continued)
Dagan 2001 not reported
Veenhoven 2003 not reported
Van Kempen 2006 not reported
WH A T ’ S N E W
Last assessed as up-to-date: 14 November 2007.
Date Event Description
9 September 2010 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 2, 2002
Date Event Description
29 April 2008 New citation required but conclusions have not
changed
New review authors.
15 November 2007 New search has been performed Searches conducted
28 April 2008 Amended Converted to new review format
26 November 2003 New citation required and conclusions have changed Substantive amendment
29 June 2003 New search has been performed Searches conducted
19 August 2000 New search has been performed Searches conducted
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N O T E S
The focus in research shifted from the use of PPVs to PCVs in children, and the role of PPVs in the prevention of AOM in children
has merely been assessed following PCVs and not as a primary intervention anymore. Therefore, the focus of the current review has
shifted from the effect of PPVs to the effect of PCVs on AOM. No further attention will be paid to the effect of PPVs, which was
described in prior versions of this review (Straetemans 2003).
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